Human Eptifibatide

<strong>Human Eptifibatide</strong>_x000D_ <strong>Catalog number:</strong> B2012288_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 1 mg_x000D_ <strong>Molecular Weight or Concentration:</strong> 832.5 g/mol_x000D_ <strong>Supplied as:</strong> Lyophilized_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20C_x000D_ <strong>Keywords:</strong> Mpr-Har-Gly-Asp-Trp-Pro-Cys-NH2, Eptifibatide_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Plosker GL, Ibbotson T. Eptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes Pharmacoeconomics. 2003;21(12):885-912._x000D_ 2: Goa KL, Noble S. Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention Drugs. 1999 Mar;57(3):439-62._x000D_ 3: Zhou X, Wu X, Sun H, Li J. Efficacy and safety of eptifibatide versus tirofiban in acute coronary syndrome patients: A systematic review and meta-analysis J Evid Based Med. 2017 May;10(2):136-144._x000D_ 4: O'Shea JC, Tcheng JE. Eptifibatide: a potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa Expert Opin Pharmacother. 2002 Aug;3(8):1199-210._x000D_ 5: Zeymer U. The role of eptifibatide in patients undergoing percutaneous coronary intervention Expert Opin Pharmacother. 2007 Jun;8(8):1147-54._x000D_ 6: Huang J, Li X, Shi X, Zhu M, Wang J, Huang S, Huang X, Wang H, Li L, Deng H, Zhou Y, Mao J, Long Z, Ma Z, Ye W, Pan J, Xi X, Jin J. Platelet integrin αIIbβ3: signal transduction, regulation, and its therapeutic targeting J Hematol Oncol. 2019 Mar 7;12(1):26._x000D_ 7: Alamin MA, Al-Mashdali A, Al Kindi DI, Elshaikh EA, Othman F. Eptifibatide-induced acute profound thrombocytopenia: A case report Medicine (Baltimore). 2022 Oct 21;101(42):e28243._x000D_ 8: Zeymer U, Wienbergen H. A review of clinical trials with eptifibatide in cardiology Cardiovasc Drug Rev. 2007 Winter;25(4):301-15._x000D_ 9: Curran MP, Keating GM. Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention Drugs. 2005;65(14):2009-35._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/32721916">10: Petrovic SS, Vasiljevska MM, Obradovic SD, Tarabar DK, Doder RB, Majstorovic IJ, Petrovic MD, Magic ZM, Cikota BM, Perisic NJ, Brcerevic IA, Manojlovic NS, Rancic NK. Antiplatelet agents'-ticagrelol and eptifibatide-safety in experimental colitis in mice Turk J Gastroenterol. 2020 Jun;31(6):451-458. </a>_x000D_ _x000D_ <strong>Products Related to Human Eptifibatide can be found at</strong> <a href="https://moleculardepot.com/product-category/Peptides/"> Peptides</a>